2010 issue 3-4


Volume 26, issue 3-4

Review article

Ziprasidone in the treatment of cognitive dysfunctions in schizophrenia

Alina Borkowska1
1. Katedra i Zakład Neuropsychologii Klinicznej UMK w Toruniu, Collegium Medicum w Bydgoszczy
Farmakoterapia w Psychiatrii i Neurologii, 2010, 3-4, 127–132
Keywords: schizophrenia, cognitive dysfunctions, ziprasidone


Cognitive dysfunctions in schizophrenia are core and enduring deficit connected with neurodevelopmental changes in the brain. Currently they are one of most important of psychopathological dimensions of the illness. The results of contemporary researches indicate, that atypical antipsychotic drugs show positive influence on different cognitive domains in schizophrenia. Ziprasidone is one of atypical neuroleptics with positive clinical effect and may be recommended as a drug for improvement cognitive abilities in schizophrenia, which is connected with its receprors profile. The ziprasidone mechanism of action is probably different in relation to cognitive functions and clinical symptoms of the illness. This may be used in schizophrenia patients, also with chronic schizophrenia with greater cognitive dysfunctions and in patients with intolerance of other drugs or without positive effect of previous treatment.

Address for correspondence:
Alina Borkowska
Katedra i Zakład Neuropsychologii Klinicznej UMK w Toruniu
Collegium Medicum w Bydgoszczy
ul Skłodowskiej-Curie 9, 85-094 Bydgoszcz
tel 52 5853702, fax 525853703, e-mail: alab@cm.umk.pl